Medscape—November 16, 2014
A blood test that measures the ratio of interferon (IFN)-beta to IFN-alpha in patients with rheumatoid arthritis can help predict who will respond to tumor necrosis factor (TNF) inhibitors, according to a new study. The study results were presented at the American College of Rheumatology 2014 Annual Meeting in Boston.
A "Shotgun" Approach
The reality today is that rheumatologists do not have the equivalent of an antibiogram — which infectious disease physicians have — so that they can tell which antibiotic is going to work in a given infection, said Stephen Paget, MD, from Hospital for Special Surgery in New York City.
"This means that we have to take a 'shotgun' approach and wait 2 to 3 months to see if these medications are going to work," he told Medscape Medical News. "And if they don't work, we put patients on another medicine."
Read full article: Medscape.
(Note: subscription is needed to view the article in its entirety)